SecBot SecBot
SC 13D ·Filed Nov 10, 2026

CMMB

Chemomab Therapeutics Ltd.
NEUTRAL
Impact 5/10
Horizonmonths Processed6d 7h ago SEC0001493152-26-051041
Activist investor acquires 5%+ stake
Actionable Insight • Neutral

Monitor the merger timeline and any amendments to the Merger Agreement. The note holders' conversion terms and the CVR distribution will determine the ultimate value transfer. Watch for any termination of the Merger Agreement, which would leave Scipher holding the ADSs as a general corporate asset.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$1.35
T+0 close · Nov 10, 2026 · via day close
Latest settled
+3.70%
T+1 · $1.40
Vs SPY
+4.06%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 11 $1.35entry
  2. T+1 · 5d ago +3.70%α +4.06% · $1.40
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Scipher Medicine Corporation filed a Schedule 13D disclosing beneficial ownership of 74,576,240 ordinary shares of Chemomab Therapeutics (10.4% of shares outstanding) acquired via 932,203 ADSs purchased at $1.18 per ADS on November 3, 2026. The stake was funded by $858,612 in new convertible notes issued to investors and $241,387 of Scipher's working capital, in connection with a planned reverse merger (Strategic Transaction) expected to close in Q1 2027. Scipher holds the ADSs for the benefit of note holders and will transfer the underlying shares to them upon merger close.

Key Financial Metrics

Stake
10.4%
Stake Value
$1.1M
Investor
Scipher Medicine Corporation

Key Facts

  • Scipher Medicine Corp filed Schedule 13D on November 10, 2026 disclosing 10.4% beneficial ownership of Chemomab Therapeutics
  • Stake consists of 932,203 ADSs representing 74,576,240 ordinary shares purchased at $1.18 per ADS on November 3, 2026
  • Total purchase price approximately $1,100,000 funded by $858,612 in new convertible notes and $241,387 working capital
  • The stake is held for the benefit of note holders who will receive the underlying shares upon closing of the planned reverse merger
  • Reverse merger (Strategic Transaction) is expected to close in Q1 2027 with combined company to trade under ticker 'SCIP'
  • Merger Agreement dated July 7, 2026 involves Chemomab, Scipher, and related entities for a redomestication and merger

Financial Impact

Scipher acquired $1.1M in Chemomab ADSs at $1.18 per ADS, representing 10.4% of outstanding ordinary shares

ownershipdilution

Risk Factors

  • Merger may not close by March 31, 2027 deadline, in which case notes remain outstanding and ADSs stay with Scipher
  • Note holders bear risk of decline in Chemomab share price while notes are outstanding
  • Scipher's working capital used for the purchase may need replenishment from future note closings

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 10 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13D Filing (Primary)0001493152-26-051041
Exhibit: ex99-4.htm0001493152-26-051041
Exhibit: ex99-5.htm0001493152-26-051041
Exhibit: ex99-3.htm0001493152-26-051041
Exhibit: ex99-6.htm0001493152-26-051041
Exhibit: ex99-8.htm0001493152-26-051041
Exhibit: ex99-1.htm0001493152-26-051041
Document: 0001493152-26-051041-index-headers.html0001493152-26-051041
Document: 0001493152-26-051041-index.html0001493152-26-051041
Document: 0001493152-26-051041.txt0001493152-26-051041

Track record

15 reports on CMMB

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +33.01% at T+60 after the Aug 19, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13D Neutral 5/10 Viewing Entry $1.35 Now $1.62 +20.00% settles Feb 9
  2. Nov 10, 20266d ago DEFA14A Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
  3. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $1.18 Now $1.62 +37.29% settles Feb 1
  4. Nov 2, 202614d ago Press Release Neutral 5/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
  5. Oct 30, 202617d ago DEFM14A Neutral 6/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
  6. Oct 19, 202628d ago 6-K Neutral 3/10 Entry $1.18 Now $1.62 +37.29% settles Jan 15
  7. Sep 30, 20266w ago 6-K Neutral 4/10 Entry $1.30 Now $1.62 +24.62% settles Dec 28
  8. Aug 19, 202612w ago 6-K Neutral 6/10 Entry $2.09 to $1.40 Now $1.62 −22.49% ▼ −33.01% −31.46% vs SPY
  9. Aug 19, 202612w ago Press Release Bearish 6/10 Entry $2.09 to $1.40 Now $1.62 +22.49% ▲ +33.01% +31.46% vs SPY
  10. Jul 8, 202618w ago 6-K Bullish 7/10 Entry $1.97 to $1.19 Now $1.62 −17.77% ▼ −39.59% −41.91% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 8h 32m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026